Marksans Pharma logo

Marksans Pharma

MARKSANS NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹14,891 Cr
Volatility
Moderate
P/E Ratio
28.54
EBITDA
₹683 Cr
Return on Equity
13.76%
Debt to Equity
0.11
Book Value
₹66.71
EPS
₹7.37
52W High
₹350.95
52W Low
₹155

Tapetide Score

Data-driven rating, 0–100. How it works →

Growth Rate

Revenue Growth
12.8% lower than 3Y
Net Income Growth
9.8% lower than 3Y
Cash Flow Change
122% higher than 3Y
ROE
-10.47% lower than 3Y
ROCE
-6.05% higher than 3Y
EBITDA Margin (Avg.)
1.17% higher than 3Y

AI Analysis — Bull vs Bear

3d ago
AI opinion · based on fundamentals
Risk medium

Marksans Pharma is a Healthcare company with a market capitalisation of about ₹15,260 crore. It trades at a P/E of 29.3x, a P/B of 5.05x and a dividend yield of 0.27%. TTM sales grew 20% and TTM profit grew 48%, both faster than its 3-year sales CAGR of 17% and 3-year profit CAGR of 16%. Return on equity has stayed between 15% and 17% across the 1-, 3-, 5- and 10-year periods. The stock returned 105% over the past year, well ahead of its 48% TTM profit growth.

Bull Case 7
  • Profit growth has picked up sharply: TTM compounded profit growth is 48%, about 3x the 3-year profit CAGR of 16% and 4x the 5-year CAGR of 12%.
  • Top-line growth is also speeding up: TTM sales growth of 20% beats the 3-year CAGR of 17%, the 5-year CAGR of 16% and the 10-year CAGR of 13%.
  • Profit is growing faster than sales. TTM profit growth of 48% against TTM sales growth of 20% points to operating leverage or better margins in the latest period.
  • Returns on capital have been steady over time. ROE was 17% over 10 years, 17% over 5 years, 16% over 3 years and 15% last year, with no year below 15%.
  • Over 10 years, profit compounded at 18% a year, ahead of 10-year sales growth of 13%. That suggests margins expanded over the full decade.
  • Over 10 years the stock returned 20% a year, close to the 18% profit CAGR. Long-run returns have broadly followed earnings growth rather than relying only on a higher valuation.
  • The P/E of 29.3x is less than the TTM profit growth rate of 48%. On trailing numbers, that gives a price-to-growth ratio below 1.
Bear Case 8
  • The stock returned 105% over one year against 48% TTM profit growth. Much of the gain came from a higher valuation, which leaves less room for disappointment.
  • Over 5 years the stock returned 38% a year while profit compounded at only 12%. The share price has risen far faster than earnings over this period.
  • The P/B of 5.05x is high relative to a latest ROE of 15%. The market is pricing in growth or margin gains that the historical 15–17% ROE range does not yet show.
  • Latest-year ROE of 15% is below the 3-year (16%), 5-year (17%) and 10-year (17%) averages, so capital efficiency has slipped slightly even as profits grew.
  • Over the medium term, margins shrank: the 5-year profit CAGR of 12% trails the 5-year sales CAGR of 16%. The 48% TTM profit jump may partly be a recovery from a low base rather than a lasting change.
  • At a P/E of 29.3x, the earnings yield is about 3.4%. That valuation depends on the recent 48% profit growth continuing, well above the 3-year CAGR of 16%.
  • The dividend yield of 0.27% is small, so shareholder returns depend almost entirely on share price gains rather than cash payouts.
  • The data does not include debt-to-equity, ROCE, EPS or 52-week price range. That limits any check of balance-sheet strength and where the stock sits in its recent trading range.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

20h ago
Neutral 1
  • Ashwamedh-Elara investor meet attendance Sep 1

    Marksans Pharma will attend the Ashwamedh - Elara India Dialogue 2026, a group meet on September 2, 2026, held in person at Hyatt, Santacruz East, Mumbai. The company said it will not share any unpublished price-sensitive information.

TL;DR: The only recent news for Marksans Pharma is a routine investor-relations disclosure about a group meet with institutional investors, which should have no direct effect on fundamentals or the share price. No new positive or negative business developments came up in this news set, so it gives no signal on whether the trend is improving or getting worse. Taking part in investor conferences suggests management is keeping in touch with institutions. Investors should look to upcoming quarterly results, US and UK formulation demand, and margin trends for clearer direction.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
500
531
586
560
591
642
682
708
620
720
754
856
841
Expenses
398
417
453
450
462
495
543
582
520
576
594
661
628
Operating Profit
102
114
133
110
128
147
139
127
100
144
161
195
213
OPM %
20%
21%
23%
20%
22%
23%
20%
18%
16%
20%
21%
23%
25%
Other Income
10
19
5
17
15
0
28
15
6
22
20
35
25
Interest
2
2
3
5
3
3
3
3
6
6
6
6
7
Depreciation
14
18
22
21
20
20
21
23
23
27
24
24
25
PBT
97
114
113
100
120
125
143
116
77
133
151
200
207
Tax %
27%
26%
26%
23%
26%
22%
27%
22%
24%
26%
25%
25%
23%
Net Profit
70
84
83
78
89
98
105
91
58
99
114
149
159
EPS in Rs
1.52
1.84
1.84
1.73
1.96
2.13
2.31
2
1.29
2.17
2.5
3.27
3.47
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
797
893
767
913
1,000
1,134
1,376
1,491
1,852
2,177
2,623
2,951
3,172
Expenses
612
757
722
834
868
942
1,037
1,232
1,513
1,719
2,090
2,350
2,458
Operating Profit
185
136
45
78
132
192
340
259
340
459
533
601
714
OPM %
23%
15%
6%
9%
13%
17%
25%
17%
18%
21%
20%
20%
22%
Other Income
3
9
7
8
5
0
7
42
59
50
66
82
102
Interest
16
10
7
10
10
9
8
8
9
11
12
24
25
Depreciation
16
28
30
27
23
27
36
45
52
74
83
99
100
PBT
156
107
15
50
104
157
302
248
338
424
504
561
691
Tax %
28%
23%
24%
28%
23%
23%
21%
25%
21%
26%
24%
25%
—
Net Profit
112
83
11
36
80
121
239
187
265
315
383
420
521
EPS in Rs
2.67
1.92
0.22
0.8
1.87
2.95
5.76
4.51
5.88
6.92
8.4
9.22
11.41
Div. Payout %
4%
21%
23%
6%
3%
3%
4%
6%
9%
9%
10%
10%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
41
41
41
41
41
41
41
41
45
45
45
45
Reserves
326
401
392
430
502
595
846
1,161
1,700
2,020
2,422
2,978
Borrowings
101
100
110
118
100
30
34
111
123
244
322
343
Other Liabilities
207
180
209
142
160
236
307
323
322
372
451
489
Total Liabilities
676
722
752
731
802
902
1,228
1,636
2,190
2,681
3,240
3,856
Fixed Assets
166
270
267
279
270
303
309
428
486
776
982
1,044
CWIP
0
0
0
0
0
0
12
3
10
9
27
59
Investments
0
0
0
0
0
0
0
0
1
27
1
0
Other Assets
510
452
484
451
533
599
907
1,205
1,694
1,869
2,230
2,753
Total Assets
676
722
752
731
802
902
1,228
1,636
2,190
2,681
3,240
3,856
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
155
31
14
50
27
233
179
99
237
230
207
458
Investing
-33
-123
-21
-39
-13
-60
-45
-84
-259
-141
-49
-249
Financing
17
-58
-3
3
-21
-114
-15
80
198
-69
-65
-71
Net Cash Flow
138
-150
-10
15
-7
60
118
94
176
21
93
138
Free Cash Flow
118
-101
-14
11
14
174
133
53
184
22
35
329
CFO/OP
108
43
31
73
41
134
67
66
88
77
62
99
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
84
89
118
71
64
78
72
97
82
76
75
80
Inventory Days
107
120
151
152
215
155
248
216
192
217
270
278
Days Payable
88
85
129
54
78
71
103
102
91
94
98
96
Cash Conversion Cycle
103
124
140
169
202
163
217
211
183
199
247
261
Working Capital Days
17
59
77
70
97
87
104
121
122
129
142
149
ROCE %
44%
23%
4%
10%
18%
25%
38%
23%
22%
21%
20%
19%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Marksans Pharma insights

69 extracted metrics + investor summaries across FY10–FY27.

Log in — free

Shareholding Pattern

Others4.42%Promot.43.87%DIIs6.19%FIIs17.47%Public28.05%As ofJun 2026

Documents

Frequently Asked Questions about Marksans Pharma

What does Marksans Pharma Ltd do?
Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products [1]
Where is Marksans Pharma Ltd (MARKSANS) listed?
Marksans Pharma Ltd trades as MARKSANS on the NSE and under code 524404 on the BSE.
Which sector does Marksans Pharma Ltd belong to?
Marksans Pharma Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Marksans Pharma Ltd?
Marksans Pharma Ltd has a market capitalisation of ₹14,891 Cr, which places it in the Mid Cap band.
What is the PE ratio of Marksans Pharma Ltd?
Marksans Pharma Ltd trades at a PE ratio of 28.54, on earnings per share of ₹7.37, against a book value of ₹66.71 per share.
What is the 52-week high and low of Marksans Pharma Ltd?
Over the last 52 weeks Marksans Pharma Ltd has traded between ₹155 and ₹350.95.
Does Marksans Pharma Ltd pay dividends?
Marksans Pharma Ltd has a dividend yield of 0.28%.
What is the Return on Equity (ROE) of Marksans Pharma Ltd?
Marksans Pharma Ltd reported a return on equity of 13.76%. Its debt-to-equity ratio is 0.11.

Company Information

Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products [1]

Website marksanspharma.com
CEO Mr. Mark B. Saldanha
Employees 1,840
Listed 2002-01-21
Face Value ₹ 1
Issued Size 45,31,63,746

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/MARKSANS.md for Marksans Pharma Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List